1.Geldenhuys WJ, Lockman PR, McAfee JH, Fitzpatrick KT, Van der Schyf CJ, Allen DD.. (2004) Molecular modeling studies on the active binding site of the blood-brain barrier choline transporter., 14 (12):[PMID:15149650][10.1016/j.bmcl.2004.04.020]
2.Zon G, Ludeman SM, Brandt JA, Boyd VL, Ozkan G, Egan W, Shao KL.. (1984) NMR spectroscopic studies of intermediary metabolites of cyclophosphamide. A comprehensive kinetic analysis of the interconversion of cis- and trans-4-hydroxycyclophosphamide with aldophosphamide and the concomitant partitioning of aldophosphamide between irreversible fragmentation and reversible conjugation pathways., 27 (4):[PMID:6708049][10.1021/jm00370a008]
3.Bard B, Carrupt PA, Martel S.. (2009) Lipophilicity of basic drugs measured by hydrophilic interaction chromatography., 52 (10):[PMID:19397318][10.1021/jm9003945]
4.Geldenhuys WJ, Allen DD, Lockman PR.. (2010) 3-D-QSAR and docking studies on the neuronal choline transporter., 20 (16):[PMID:20637607][10.1016/j.bmcl.2010.06.090]
5.PubChem BioAssay data set,
6.Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W.. (2011) FDA-approved drug labeling for the study of drug-induced liver injury., 16 (15-16):[PMID:21624500][10.1016/j.drudis.2011.05.007]
7.Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.. (2011) Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps)., 7 (12):[PMID:22194678][10.1371/journal.pcbi.1002310]
8.USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date,
9.PubChem BioAssay data set,
10.WHO Anatomical Therapeutic Chemical Classification,
11.Ellen Van Damme. (2021) Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity, [10.6019/CHEMBL4651402]